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Abstract. Vascular endothelial growth inhibitor (VEGI) has
been associated with tumour-related vasculature in certain
maligancies. However, its implication in prostate cancer
remains unknown. We investigated the expression pattern
and role of VEGI in prostate cancer and prostate cancer cells.
The expression of VEGI was examined in human prostate
tissue and prostate cancer cell lines. The biological impact of
modifying the expression of VEGI in prostate cancer cells
was evaluated using in vitro models. VEGI mRNA was
expressed in a wide variety of human prostate cancer cell
lines and most prostate specimens. VEGI protein was seen in
normal prostate epithelium, but was decreased or absent in
prostate cancer specimens, particularly in tumours with high
Gleason scores. Moreover, forced-expression of VEGI led to
a decrease in the motility and adhesion of prostate cancer cells
in vitro. In contrast, knocking down VEGI in the cells resulted
in an increase in motility and adhesion. Interestingly, both
forced-expression and knocking down of VEGI had no
bearing on growth and invasive capacity of prostate cells. In
conclusion, the expression of VEGI is decreased in prostate
cancer and is almost absent in tumours with high Gleason
scores. Together with its inhibitory effect on cellular motility
and adhesion, this suggests that VEGI functions as a negative
regulator for aggressiveness during the development and
progression of prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed male
cancer in Western countries and the second leading cause of
cancer deaths in men (1,2). Despite the improvements in both
early detection and treatment, we are still facing significant
challenges in managing this disease.
Vascular endothelial growth inhibitor, VEGI [also known
as tumour necrosis factor superfamily member 15 (TNFSF15)
and TNF ligand related molecule 1 (TL1)], is a recently
identified anti-angiogenic cytokine that belongs to the
TNFSF (3-5). Three isoforms of VEGI have been reported,
all sharing a common 151 C-terminal amino acid sequence
but differing in their N-terminal regions (6-8). Its transcript was
found to be expressed in the placenta, lung, kidney, skeletal
muscle, pancreas, spleen, small intestine, prostate and colon.
The secreted soluble form of VEGI has been demonstrated as
a potent anti-angiogenic factor through inhibiting prolife-
ration of endothelial cells (7-9). Previous studies have
demonstrated an intricate relationship between VEGI and
carcinoma in vitro and in vivo. VEGI has been shown to
suppress the growth of colon carcinoma cells (murine colon
cancer cells, MC-38) both in vitro and in vivo (4,10). Systemic
administration of VEGI markedly inhibited tumour growth
and increased survival time in a Lewis lung cancer (LLC)
murine tumour model (11). Parr et al reported that patients
with breast tumours expressing reduced levels of VEGI had a
higher local recurrence, shorter survival time and an overall
poorer prognosis than those patients expressing high levels of
VEGI (12). This suggests that the anti-tumour activity of
VEGI may not be due to a direct effect on cancer cells, but
rather due to interference with the development of tumour-
associated vasculature. VEGI had no inhibitory activity on
the growth of cancer cells in vitro (4,5,8,10,13).
Despite these observations of VEGI in solid tumours, its
role in prostate cancer remains unknown. In the current
study, the expression of VEGI was examined in human
prostate tissues, prostate tumours, and in prostate cancer cell
lines. The biological function of this molecule was investigated
in prostate cancer cells, in which the expression of VEGI
was manipulated using genetic methods.
Materials and methods
Materials. Prostate tissue samples were snap-frozen in liquid
nitrogen immediately after radical prostatectomy, transurethral
prostatectomy or prostate biopsy. All protocols were reviewed
and approved by the local ethics committee and all patients
gave written informed consent. PC-3 (ECACC, Salisbury,
UK); DU-145, LNCaP, CA-HPV-10 and PZ-HPV-7 (ATCC);
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PNT-1A and PNT-2C2 (kindly provided by Professor N.
Maitland, University of York) were used. Monoclonal mouse
anti-human-VEGI was purchased from Santa Cruz Bio-
technology, Inc. (SC-53975, CA, USA).
RNA isolation and reverse transcription PCR. RNA was
isolated using total RNA isolation reagent (ABgene, Epsom,
UK). Reverse transcription and PCR was performed using
standard methods.
Immunohistochemical and immunocytochemical staining of
prostate specimens and cells. Prostate tumour (n=20) and
normal prostate (n=11) tissue was sectioned using a cryostat,
and verified by two pathologists. For immunocytochemical
staining of VEGI expression, cells were fixed and then
permeabilized with 0.1% Triton for 5 min in TBS. Following
blocking with horse serum, the samples were probed with
anti-VEGI antibody, and labelled with a biotinylated secondary
antibody, and subsequently visualised using Vectastain Uni-
versal Elite ABC kit (Vector Laboratories, Peterborough, UK).
Construction of VEGI expressing and ribozyme transgenes
and transfection (14,15). The full-length human VEGI
coding sequence and hammerhead ribozyme targeting human
VEGI were cloned into a mammalian expression plasmid
vector (pEF/His TOPO TA, Invitrogen, Inc., Paisley, UK).
Full primer sequences are provided in Table I. Empty control
plasmids or plasmids containing VEGI expression sequence
or ribozyme transgenes were then transfected into cells
using electroporation. After selection with blasticidin, the
transfectants were used in the studies.
Real-time quantitative polymerase chain reaction (Q-PCR)
(12,16). Real-time quantitative PCR was carried out using
the iCycleriQ5 system (Bio-Rad, Hemel Hemstead, UK) to
determine the level of expression of the VEGI transcripts in
the cell lines. GAPDH was used as a quantitative control.
Cell growth assay (17). Cells were seeded into a 96-well
plate (2,500 cells/well). Cell growth was assessed after 1, 3
and 5 days. Crystal violet was used to stain the cells, and the
absorbance was determined at a wavelength of 540 nm using
a spectrophotometer (BIO-TEK, Elx800, UK).
Wounding assay (14,15). The migration of the cells was
determined using wounding assay. A monolayer of cells was
scraped with a fine gauge needle. The movement of cells
close to the wound was recorded on a digitised time lapse
video recorder and analyzed using an imaging analysis tool
(OPTIMAS).
Motility assay using Cytodex-2 beads (14,15). Cells (1x106)
were incubated with 100 μl of cytocarrier beads overnight.
The beads were washed twice to remove any dead cells, and
then re-suspended. One hundred microliters of beads/cells
were transferred into a 24-well plate. After incubation for 4
h, the cells were fixed in 4% formalin and stained with 0.5%
crystal violet, before counting.
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Table I. PCR primer sequences.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Primer Forward Reverse
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
hGAPDH 5'-AGCTTGTCATCAATGGAAAT 5'-CTTCACCACCTTCTTGATGT
hGAPDH(Q-PCR) 5'-CTGAGTACGTCGTGGAGTC 5'-ACTGAACCTGACCGTACACAGAGATG
ATGACCCTTTTG
Z-sequence
VEGI 5'-ATGAGACGCTTTTTAAGCAA 5'-CTATAGTAAGAAGGCTCCAAAG
VEGI (Q-PCR) 5'-CAAAGTCTACAGTTTCCCAAT 5'-ACTGAACCTGACCGTACATGATTTTTA
AAGTGCTGTGTG
Z-sequence
VEGI (ribozyme1) 5'-CTGCAGTCATTGGGAAACTGT 5'-ACTAGTGAGACGCTTTTTAAGCAAAGT
ACTGATGAGTCCGTGAGGA TTCGTCCTCACGGACT
VEGI(ribozyme2) 5'-CTGCAGTCTCACAACTGGAAA 5'-ACTAGTTAATCCTCTTTCTTGTTTCGTC
CTGATGAGTCCGTGAGGA ACGGACT
VEGI (expression) 5'-ATGAGACGCTTTTTAAGCAA 5'-CTATAGTAAGAAGGCTCCAAAGA
Primers for T7F: TAATACGACTCACTATAGGG BGHR: TAGAAGGCACAGTCGAGG
detecting plasmid
Primers to detect RBTPF: CTGATGAGTCCGTGAGG RBBMR: TTCGTCCTCACGGACTCATCAG
ribozymes ACGAA
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1473-1480.qxd  9/10/2009  12:04 ÌÌ  Page 1474
Invasion assay (14,15). Transwell inserts with 8 μm pore size
were coated with 50 μg Matrigel (BD Matrigel™ Basement
Membrane Matrix) and air dried. After rehydration, 20,000 cells
were added to each well. After 96 h cells that had migrated
through the matrix to the other side of the insert were fixed,
stained and then counted under a microscope.
Cell-matrix adhesion assay (15,18). Cells were seeded into a
96-well plate which had been pre-coated with Matrigel (5 μg/
well). After 40 min of incubation, non adherent cells were
washed off using BSS. The adhered cells were fixed, stained
and then counted.
Electric cell-substrate impedance sensing (ECIS) based
motility assay (19). The ECIS-1600R model instrument and
8W10 arrays (Applied Biophysics, Inc., NJ) were used in this
study. Cells (300,000) were added to each well of the ECIS
arrays. After 3 h when confluency was reached, the monolayer
was electrically wounded at 6 V for 30 sec for each well.
Impedance and resistance of the cell layer were immediately
recorded for a period of up to 20 h.
Statistical analysis. All statistical analysis was performed
using the SPSS 16.0 software. The two sample t-test was
used for normally distributed data. Fisher's exact test was
used for analysing immunohistochemical staining in prostate
tissues. Differences were considered to be statistically signifi-
cant at P<0.05.
Results
The expression of VEGI in prostate tissues and cell lines. The
expression of VEGI was examined in seven prostate cell lines
and human prostate tissues using conventional RT-PCR.
VEGI transcript was detectable in most cell lines except CA-
HPV-10 (Fig. 1A). It was also detected in 9 of 11 normal
prostate tissues, and 17 of 20 prostate cancer tissues (Fig. 1B).
In immunohistochemical staining, VEGI was seen in normal
prostate epithelia cells, but the staining was decreased or
absent in prostate cancer cells, particularly in specimens with
higher Gleason scores (Fig. 1C). The positive staining of
normal tissue (81.8%, 9/11) was significantly higher than that
of prostate cancer tissues (25%, 5/20), P=0.007.
Genetic manipulation of VEGI levels in prostate cancer cell
lines. PC-3 cells, which expressed modest levels of VEGI
transcript, were transfected with a VEGI expression construct
and anti-VEGI ribozyme transgenes, to respectively create
sublines showing enhanced or suppressed levels of VEGI
expression. DU-145 cells, which expressed lower levels of
VEGI transcript, were only transfected with the VEGI
expression construct. As shown by RT-PCR analysis, VEGI
mRNA expression was significantly increased in DU-
145VEGIexp4 cells compared with wild-type (DU-145wt) and
plasmid control (DU-145pEF/His) cells (Fig. 2A). Q-PCR also
demonstrates that VEGI mRNA expression was significantly
increased in DU-145VEGIexp4 and PC-3VEGIexp4 cells, and
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Figure 1. VEGI expression in prostate cancer tissues and cell lines. (A) Detection of the VEGI transcript using RT-PCR in a panel of human prostate cell
lines. (B) Detection of the VEGI transcript in a panel of normal and tumour tissues. GAPDH was used as the housekeeping control. (C) Immunohistochemical
staining of human prostate specimens. C1 and C2 are normal prostate tissues. The VEGI protein was found to be intensively stained in the cytoplasmic area of
normal prostate epithelial cells (indicated by black arrows). C3 and C4 are prostate cancer tissues with a Gleason score of 7. VEGI was only weakly stained in
these cells (black arrows). C5 and C6 are prostate cancer tissues with a Gleason score of 9. The VEGI protein staining was nearly absent (white arrows). That
is, VEGI expression was seen to be negative or weakly positive in the cancer cells of prostate cancer tissue. C7 is a negative control with normal prostate
tissue. C8 is a positive control with DU-145VEGIexp4. The VEGI was forcibly-expressed in the cytoplasmic area.
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decreased in PC-3VEGIrib2 cells, compared to corresponding
controls (Fig. 2B and C). Forced expression and knockdown
of VEGI was also reflected at the protein level in immuno-
cytochemical staining: a decrease in the VEGI protein level
was seen in PC-3VEGIrib2 cells, and increased staining was
seen in DU-145VEGIexp4 and PC-3VEGIexp4, compared to controls
(Fig. 2D-G).
The influence of VEGI expression on cell matrix adhesion
and motility of prostate cancer cells. We first examined the
effect of VEGI on cell-matrix adhesion of prostate cancer
cell lines. Overexpression of VEGI exhibited a significant
inhibitory effect on cell-matrix adhesion of the cells (Fig. 3A).
Compared with DU-145wt (32.4±4.27) and DU-145pEF/His
(31.6±4.95), the number of adherent cells for DU-145VEGIexp4
(16.1±5.28) was significantly reduced (p<0.001 vs. both
controls). In line with the observation from DU-145 cells, the
number of adherent cells for PC-3VEGIexp4 and PC-3VEGIrib2 was
35.2±13.40 and 89.4±22.06, respectively (Fig. 3B), p<0.001
compared with both PC-3wt (61.8±6.62) and PC-3pEF/His cells
(61.8±12.52).
In the cytocarrier based cell motility assay, cell motility
was significantly reduced in DU-145VEGIexp4 and PC-3VEGIexp4
cells. The number of migrating DU-145VEGIexp4 cells was
11.0±3.77 compared with 26.3±6.46 for DU-145wt cells and
28.8±6.94 for DU-145pEF/His cells (p<0.001). The number of
migrating PC-3VEGIexp4 cells was 28.5±8.89, compared with
46.0±10.49 for PC-3wt cells and 38.8±11.97 for PC-3pEF/His
cells (p<0.001). The number of migrating PC-3VEGIrib2 cells
was 90.8±29.02. It was also significantly higher than that of
PC-3wt cells and PC-3pEF/His cells, p<0.001 (Fig. 4A and B).
To further investigate the effect of forcibly expressing
VEGI on cell motility, the ECIS system was utilised to
determine the migration of DU-145 cells. The migrating
capacity was remarkably reduced in DU-145VEGIexp4 cells
compared with DU-145wt and DU-145pEF/His cells (Fig. 4C).
In the wounding assay, we also found that the motility
was reduced significantly in cells containing the VEGI
expression construct, and increased in cells showing VEGI
knockdown. The average migrating distance of DU-145VEGIexp4
and PC-3VEGIexp4 was 12.1±11.97 μm and 56.7±9.24 μm, respec-
tively; p<0.001 compared to both DU-145wt (74.7±7.76 μm)
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Figure 2. Confirmation of manipulation of VEGI expression in prostate cancer cells. (A and B) Verification of forced expression of the VEGI transcript in
DU-145 cells. Representative image from 4 experiments showing results of the RT-PCR (A), where VEGI mRNA was overexpressed in DU-145VEGIexp4 cells
compared with the wild-type and empty plasmid control cells. Q-PCR confirmed the overexpression of VEGI mRNA in DU-145VEGIexp4 cells compared with
DU-145wt and DU-145pEF/His (p<0.01) cells. Asterisk indicates p<0.01 vs. DU-145wt and DU-145pEF/His cells. (C) Verification of forced expression and
knockdown of VEGI transcript in PC-3 cells, using Q-PCR. Asterisk indicates p<0.01 vs. PC-3wt and PC-3pEF/His cells. Q-PCR was performed in triplicates for
each cell line and repeated independently three times. (D and E) Forced expression and knockdown of VEGI at protein level using immunocytochemistry
staining for DU-145 and PC-3 cells. VEGI protein was stained stronger in the cytoplasmic areas of DU-145VEGIexp4 and PC-3VEGIexp4 cells than that of wild-type
and empty plasmid control cells. VEGI protein level was almost eliminated in PC-3VEGIrib2 cells compared with the wild-type and empty plasmid control cells.
(F and G) The staining density of VEGI was quantified and normalised for PC-3 and DU-145 cells. Asterisk indicates p<0.01 vs. wild-type and empty plasmid
control cells. Error bars represent the SD.
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and DU-145pEF/His (61.2±22.08 μm) cells, PC-3wt (97.7±
12.93 μm) and PC-3pEF/His (69.4±15.17 μm) cells. Knock-
down of VEGI increased the motility of PC-3VEGIrib2 cells, the
distance of cell movement was 117.7±19.96 μm, p=0.067
and 0.016 compared to both PC-3wt and PC-3pEF/His cells,
respectively (Fig. 5A and B).
Manipulation of VEGI expression had no impact on growth
and invasiveness of prostate cells. The influence on cell
growth and invasion by VEGI was also examined using in vitro
growth and invasion assay, respectively. There was no differ-
ence seen in the growth of prostate cancer cells by modified
VEGI expression. The invasive capacity of PC-3VEGIexp4,
PC-3VEGIrib2 and DU-145VEGIexp4 cells did not show any change
compared with that of wild-type and empty plasmid control
cells (p>0.05) (Fig. 6).
Discussion
VEGI was originally thought to be exclusively expressed in
endothelial cells (20). Subsequently, it has been reported that
VEGI is also expressed in a wide variety of human cancer
cell lines, including breast, prostate, bladder, colorectal and
liver (12). The role of VEGI in human cancer cells has been
investigated recently (21). Chew et al reported that over-
expression of VEGI in endothelial cells caused dose-dependent
cell death (8). VEGI is also able to inhibit the growth of
xenograft tumours and reduce microvessel density. In 2005,
Hou et al, using a Lewis lung cancer (LLC) murine tumour
model, demonstrated that systemic administration of VEGI
gave rise to a marked inhibition of tumour growth and to an
increase in survival time of the treated animals (11). Zhai
et al also reported that VEGI markedly inhibited the growth
of breast and colon xenograft tumours, and suggested that
this may be indirectly through the ability of VEGI to inhibit
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Figure 3. VEGI expression and in vitro cell-matrix adhesion. All experi-
ments were repeated 5 times. (A) Forced expression of VEGI reduced the
number of adherent cells in DU-145VEGIexp4 cells. Asterisk indicates p<0.01
vs. DU-145wt and DU-145pEF/His cells. (B) Reduced adhesion was also seen in
PC-3VEGIexp4 cells. Whereas, knockdown of VEGI inversely increased
adhesion in PC-3VEGIrib2 cells. Asterisk indicates p<0.01 vs. PC-3wt and
PC-3pEF/His cells. Cell matrix adhesion assay carried out using 5 wells per
cell line per experiment. Error bars represent the SD.
Figure 4. The effect of forced expression VEGI on migration of PC3 and
DU145 cells. All experiments were repeated 4 times. (A) The motility of
PC-3VEGIexp4 cells was markedly reduced, and that of PC-3VEGIrib2 cells was
increased inversely, compared with wild-type and empty plasmid control
cells. Experiments were done in 6 wells per cell. Asterisk indicates p<0.01
versus PC-3wt and PC-3pEF/His cells. (B) A decrease in motility was seen in
DU-145VEGIexp4 cells. Asterisk indicates p<0.001 vs. DU-145wt and DU-
145pEF/His cells. (C) Effect of VEGI expression on cell migration as analysed
by ECIS (wounding assays). Cells were first wounded at 6 V for 30 sec. The
impedance change is shown. The DU-145VEGIexp4 cells which overexpress
VEGI showed a marked reduction in migration. Error bars represent the SD.
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Figure 5. The effect of forced expression of VEGI on migration assay (scratch wounding assay). All experiments were repeated 3 times. (A) The movement
power was reduced significantly in DU-145VEGIexp4 cells compared with wild-type and empty plasmid control cells (p<0.01). (B) The movement power was
reduced significantly in PC-3VEGIexp4 cells (both p<0.01) and increased in PC-3VEGIrib2 cells (p=0.067 and 0.016, respectively) compared with wild-type and
empty plasmid control cells. Error bars represent the SD.
Figure 6. The effect of modified expression of VEGI on growth and invasiveness of prostate cells. (A and B) The growth capacity of PC-3VEGIexp4, PC-3VEGIrib2
and DU-145VEGIexp4 cells did not show any difference from that of wild-type and empty plasmid control cells (p>0.05). (C and D) The invasiveness of
PC-3VEGIexp4, PC-3VEGIrib2 and DU-145VEGIexp4 cells did not show any difference from that of wild-type and empty plasmid control cells (p>0.05).
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capillary-like structure growth (4,5). These studies suggest
that VEGI is able to induce apoptosis in endothelial cells via
an autocrine pathway but the same was not seen in other cell
types examined (5,9). Overall, early evidence has indicated
that the anti-tumour activity of VEGI is more likely to be the
result of an interference with the development of tumour-
associated vasculature rather than that of a direct effect on
tumour cells (10,11,13,22). However, it has also been
suggested that VEGI may inhibit the growth of human tumour
cell lines, including human histiocytic lymphomas (U-937),
human breast carcinomas (MCF-7), human epithelial carci-
noma (HeLa) and human myeloid lymphomas ML-1a (23).
So far, there is little work on the significance of VEGI in
prostate cancer. The present study revealed that VEGI mRNA
was expressed in a wide variety of human prostate cancer
cell lines, and most prostate specimens. Due to the fact that
mRNA samples used in the present study were a result of
homogenisation of biopsied tissues, it is difficult to decipher
the source (normal epithelial, cancer, or stromal cells) of the
VEGI mRNA transcript, rather than showing the presence of
the transcript in the test tissues. However, the immunohisto-
chemical analysis clearly indicates the origin of VEGI protein
in human prostate cancer tissue. VEGI protein was found to
be expressed at low levels within the prostate cancer cells,
and was almost absent in tumours with high Gleason scores.
The absence or reduction of tumour VEGI expression
suggests that there may be a shift in the balance between pro-
and anti-angiogenic stimuli. This loss of balance may
subsequently produce a microenvironment that is conducive
to tumour growth and survival (12,22,24). Moreover, our
results confirm that forced-expression of VEGI can directly
affect the motility and adhesion of prostate cancer cells. The
number of adherent cells in VEGI forced-expression cells
exhibited a near 50% decrease compared with the wild-type
cells. The average distance of VEGI force expression cells
was also decreased dramatically compared with controls.
This was also supported by the observations from VEGI
knockdown cells, which exhibited increased motility and
adhesion. VEGI can directly reduce aggressiveness of prostate
cancer cells, which is in line with the decreased expression of
VEGI in prostate cancer specimens. Together with the obser-
vations that VEGI has little bearing on growth of prostate
cancer cells, these data argue for a pivotal role of VEGI as a
cell adhesion and migration regulator. This presents an
exciting direction to pursue in future scientific research.
In addition to the effect on endothelial cells and cancer
cells, VEGI may be involved in other aspects of cancer. VEGI
was highly expressed in activated dendritic cells (DCs), in
activated lymphocytes, and in plasma cells, and monocytes
(20,25-27). It is also a T cell co-stimulator. It can directly
stimulate DC maturation, and induce nuclear factor-κB
activation, and apoptosis in death receptor-3-expressing cell
lines. However, it is unclear whether activation of tumour-
specific or non-specific B or T lymphocytes, or induction of
cytokines may also operate in VEGI-mediated tumour
suppression. Collectively, it is suggested that modulating
VEGI may eventually be exploited as a therapeutic strategy
in prostate cancer.
In conclusion, the present study shows that VEGI
expression is decreased in prostate cancer, particularly in
tumours with higher Gleason Scores. VEGI, a potential cell
migration and adhesion regulating protein of TNFSF, is
inversely associated with the aggressiveness of human prostate
cancer cells. This is likely via its inhibitory role on cell
migration and adhesion. Our results suggest that VEGI may
be a putative tumour suppressor and a potential therapeutic
target.
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